Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc.

Overview
Date Founded

1995

Headquarters

8800 Technology Forest Place, The Woodlands, TX, 77381, USA

Type of Company

Public

Employees (Worldwide)

184

Industries

Pharmaceuticals
Medical Support Services
Computer Software
Biotechnology

Company Description

Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. The Genome: Our Source of Discovery We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. A Diverse Pipeline of Targeted Therapies Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.

Contact Data
Trying to get in touch with decision makers at Lexicon Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer & Director

Executive Vice President & Chief Financial Officer

Secretary, Vice President & General Counsel

Executive Vice President-Corporate Development

Executive Vice President, Innovation & Chemical Sciences

Executive Vice President, Research & Development

Vice President, Finance & Accounting

Co-Founder

Executive Director-Corporate Communications

Executive Director of Biostatistics

Board of Directors

Founder at The Invus Group LLC

President & Chief Executive Officer & Director at Lexicon Pharmaceuticals, Inc.

Former Managing Director, Private Equity, New York at The Invus Group LLC

Former President, United States Pharmaceuticals at Bristol-Myers Squibb Company

Chief Executive Officer at Wellmark International, Inc.

Investigator at Howard Hughes Medical Institute, Inc.

Founder at Synecor LLC

Paths to Lexicon Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Lexicon Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Invus Public Equities Advisors makes majority investments in private, high growth companies. The firm also takes significant, long-term positions in public companies whose fundamentals and management they believe in. Invus focuses on investments in the stocks of small- to mid-cap companies that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is measured in years. Invus invests in a variety of industries, including but not limited to, consumer products and services, food, specialty retail, software, biotechnology, medical devices, healthcare products and professional services.

Details Hidden

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

Details Hidden

Ulys LLC is an investment advisor located in New York City. The firm is a subsidiary of private equity group, the Invus Group LLC.

Recent Transactions
Details Hidden

Lexicon Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Lexicon Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Lexicon Pharmaceuticals, Inc. raised money in a private placement transaction

Insider Transactions
Transaction Advisors
Underwriter

Advised onLexicon Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onLexicon Pharmaceuticals, Inc. issued USD Common Stock

Selling Group Member

Advised onLexicon Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onLexicon Pharmaceuticals, Inc. issued USD Common Stock

Managing Director

Advised onLexicon Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Head of US Capital Markets & Managing Partner of Silicon Valley Office at Freshfields Bruckhaus Deringer LLP

Advisor

Partner, Audit Services at Grant Thornton LLP

Consultant

Senior Vice President, Functional Genomics & Chief Velocigene Operations at Regeneron Pharmaceuticals, Inc.

Clients

Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The Consumer Healthcare segment include brands such as Smecta, a naturally extracted purified clay for the symptomatic treatment of acute diarrhea; Tanakan, a standardized extract from the leaves of Ginkgo biloba for the treatment of various neurological and neuro-sens or ial disorders; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; and Fortrans, a colon cleansing solution indicated for patients in preparation for endoscopic, radiological examinations or colonic surgery. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

Key Stats and Financials As of 2019
Market Capitalization
$1.2B
Total Enterprise Value
$460M
Earnings Per Share
$1.11
Three Year Compounded Annual Growth Rate Of Revenue
56.93%
Debt TEV
0.54x
TEVNet Income
3.53x
Enterprise Value EBITDAOperating
2.64x
Enterprise Value / Sales
1.43x
Total Equity
$117M
Total Debt
$247M
EBITDAMargin
53.94%
EBITDA
$174M
Net Profit
$130M
Revenue
$322M
Non-Profit Donations & Grants
$500 - $15K
2014
Non-Profit Donations & Grants Received
Investments
Details Hidden

Symphony Icon, Inc. engages in the manufacture of pharmaceutical products. The company was founded in June 2007 and is headquartered in Rockville, MD.

Investors
Details Hidden

BCM Technologies (BCMT) focuses on early-stage investments in the life sciences sector. The firm seeks opportunities with considerable commercialization potential, clear competitive advantages in existing markets and innovative early entrants in growing niche markets. They provide seed capital for proof-of-concept research and play an active role in structuring and developing start-up companies. BCMT's initial investments are often used to validate a technology through highly-focused research activities. These initial investments frequently precede the recruitment of a management team. The firm prefers to lead seed and first rounds and to continue to co-invest in later rounds.

Details Hidden

Apax-UK is an active, long-term, sector-focused manager which invests through their funds, aiming to grow businesses by acting as a catalyst for change. They focus on the consumer, healthcare, services and tech & telco sectors, generally holding an investment for five years.The firm typically invests in large companies with an enterprise value between EUR 1-5 billion, seeking to identify opportunities where capital, experience and insight can release potential and lead to significant growth. They partner with management, taking a board seat on their investee firms, aiming to create long-term value.Apax-UK’s global sector teams source and review potential investment opportunities with their Operational Excellence practice. Their Digital practice group invests in businesses that derive the vast majority of their revenues directly from online and/or digital activities. They leverage their experience to provide solutions and support to investee companies including expertise in site monetization, conversion, multivariate testing, search engine marketing and data architecture.The Operational Excellence team is dedicated to helping investee companies release potential by assisting them in specific areas such as devising new strategy, testing the sales effectiveness of a new website or cutting procurement costs. Financing of their investments is optimized through their Capital Markets practice, including debt and equity issuance, debt and equity syndication, restructuring and Forex.

Details Hidden

Co-Founder at Lexicon Pharmaceuticals, Inc.

Suppliers
Bristol-Myers Squibb Company Medical Support Services | New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

TAKE Solutions Ltd. Management Consulting | Chennai, Ind

TAKE Solutions Ltd. engages in the scientific research and development. It operates through the Life Sciences and Supply Chain Management segments. The Life Sciences segment support drug development R&D process with Clinical Research Organization services as a major component. The Supply Chain Management segment focuses on niche engineering services, supply chain collaboration, and product re-engineering. The company was founded by Harikesavanallur Ramani Srinivasan and Devaki Venkataraman Ravi on December 20, 2000 and is headquartered in Chennai, India.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Novartis AG Pharmaceuticals - Basel, Switzerland

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Lexicon Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Lexicon Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Lexicon Pharmaceuticals, Inc..